Companies: 10,795·Total market cap: $144.5T
MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLTNASDAQHealthcare● Active
$29.46
+$1.45(+5.18%)
Market Cap$23253897
P/E Ratio
52W High$33.28
52W Low$12.24

MapLight Therapeutics, Inc. (MPLT) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

mplt · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for MapLight Therapeutics, Inc. (MPLT) measures how much investors pay for each dollar of the company's trailing earnings. MPLT's current PE ratio of N/A is calculated by dividing its stock price of $29.46 by its TTM earnings per share of -$4.41.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-4.26
Based on 6 analysts
EPS (TTM)
-$4.41
TTM · diluted EPS
PEG Ratio
0.09
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MapLight Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2022 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc.You
MPLT
$23MN/A-$4.41
BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.
BRTX
$3MN/A-$1.58
Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc.
DWTX
$3MN/A-$4.17
Edesa Biotech, Inc.
Edesa Biotech, Inc.
EDSA
$48MN/A-$1.27
Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc.
ERNA
$2MN/A-$55.83
Immuron Limited
Immuron Limited
IMRN
$8MN/A-$0.90
Lipocine Inc.
Lipocine Inc.
LPCN
$12MN/A-$1.77

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 4 of 4 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-3.66
2024-12-31
FY2024
$-1.87
2023-12-31
FY2023
$-1.34
2022-12-31
FY2022
$-0.72

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for MapLight Therapeutics, Inc. (MPLT) measures how much investors pay for each dollar of the company's trailing earnings. MPLT's current PE ratio of N/A is calculated by dividing its stock price of $29.46 by its TTM earnings per share of -$4.41.

PE Ratio = Stock Price ÷ EPS (TTM)
= $29.46 ÷ -$4.41 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

MPLT pe ratio · 6 questions

MPLT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $29.46 and TTM EPS of -$4.41. Data sourced from Financial Modeling Prep via MPLT's SEC 10-K and 10-Q filings.

MPLT PE ratioWhat is MPLT PE ratioCurrent PE ratio of MPLTMPLT PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MapLight Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09